Cedazuridine

Phase 2Small molecule

Takeda

Cedazuridine is one of 99 small molecule programs targeting Acute Myeloid Leukemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myeloid LeukemiaActive, not recruiting

Myelodysplastic SyndromesActive, not recruiting

Myeloid NeoplasmActive, not recruiting

Acute Myeloid LeukemiaPhase 2

Active, not recruiting

Myelodysplastic SyndromesPhase 2

Active, not recruiting

Myeloid NeoplasmPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

804 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Novantrone

Pfizer

Phase 3

32 2

Rydapt

Novartis

Phase 3

17 3

Cytoxan

BBaxter Healthcare Corporation

Phase 3

28 4

Zolinza

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

4 5

Standard Chemotherapy

Roche

Phase 3

1 6

AG-120

Institut de Recherches Internationales Servier

Phase 3

4 7

Oblimersen Sodium

NNational Cancer Institute (NCI)

Phase 3

3 8

Low-Dose Cytarabine

Bristol-Myers Squibb

Phase 3

2 9

Amsacrine

EEuropean Organisation for Research and Treatment of Cancer - EORTC

Phase 3

3 10

Grafalon

FFundación Canaria de Investigación Sanitaria

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Active, not recruiting

Solid Tumors

NCT03875287

Q4 2028

Phase 2/3Recruiting

Myeloid Neoplasm

NCT04256317

Clinical

Trials by Indication[1]

Myeloid Neoplasm1 trial

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Recruiting· Taiho Oncology, Inc. logo

Taiho Oncology, Inc.·Phase 2/3·NCT04256317·316 enrolled

Solid Tumors1 trial

Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors

Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT03875287·35 enrolled

Myelodysplastic Syndromes1 trial

A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes

Withdrawn· Takeda logo

Takeda·Phase 2·NCT04985656

ESS1 trial

Thorough QT Assessment of Cedazuridine in Healthy Subjects

Completed·AAstex Pharmaceuticals, Inc.·Phase 1·NCT04953923·36 enrolled

Acute Myeloid Leukemia1 trial

Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant

Terminated·SSanjay Mohan·Phase 2·NCT05799079·1 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Cedazuridine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cedazuridine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cedazuridine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Takeda

Cedazuridine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2028

Trials by Indication[1]

Myeloid Neoplasm1 trial

Solid Tumors1 trial

Myelodysplastic Syndromes1 trial

ESS1 trial

Acute Myeloid Leukemia1 trial

References

Drug Info

Quick Facts

Related News